Abstract Number: 0910 • ACR Convergence 2023
17β-estradiol and B-cell Intrinsic Type I Interferon Amplify Toll-like Receptor 7 Signaling Loop in B Cells of Female Lupus Prone BXD2 Mice
Background/Purpose: While systemic lupus erythematosus (SLE) disproportionally affects women versus men, elevation in estradiol (E2) alone is not sufficient to promote the development of autoantibody…Abstract Number: 0931 • ACR Convergence 2023
Down-Regulation of Human NADH-Ubiquinone Oxidoreductase Chain 6 by N6-Methyladenosine Methylation Is Associated with Lupus CD4+ T Cell Activation
Background/Purpose: Recently mitochondria have been recognized as a key player in the pathogenesis of systemic lupus erythematosus (SLE). Given that N6-methyladenosine (m6A) modifications can regulate…Abstract Number: 1227 • ACR Convergence 2023
Serious Infections Following Rituximab Administration in Children with Systemic Lupus Erythematosus
Background/Purpose: Rituximab has been associated with high rates of infection among adults with systemic lupus erythematosus. However, studies of infection risk following rituximab among children…Abstract Number: 1356 • ACR Convergence 2023
Reproductive History and HPV Vaccination Awareness Among Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Background/Purpose: Women with systemic rheumatic diseases (SRDs), particularly those with SLE, may be more vulnerable to HPV infection and HPV-related cervical cancer. However, HPV testing…Abstract Number: 1453 • ACR Convergence 2023
Musculoskeletal Involvement in Systemic Lupus Erythematosus: Insights from a Survey of Lupus Experts
Background/Purpose: Musculoskeletal manifestations of systemic lupus erythematosus (SLE) are common, consisting ofarthralgia and arthritis (95%), myalgia/myositis (17%), tenosynovitis, and bursitis (12%). Joint involvement is a…Abstract Number: 1470 • ACR Convergence 2023
SARS-CoV-2 Antibody Formation After COVID-19 Vaccination in SLE Patients Treated with Belimumab: Single-Center Prospective Observational Study
Background/Purpose: Patients with systemic lupus erythematosus (SLE) should be more proactive with the administration of the COVID-19 vaccine, as their systemic conditions are prone to…Abstract Number: 1487 • ACR Convergence 2023
Prevalence of Objectively Measured Sleep Disturbance in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Self-reported poor sleep is common in SLE, but few studies have objectively measured sleep have been conducted. In general population studies, sleep disorders are…Abstract Number: 1504 • ACR Convergence 2023
Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab — Observations from the American Rheumatology Network (ARN) in the U.S
Background/Purpose: FDA-approved for moderate-severe SLE in August 2021, anifrolumab is a type I interferon (IFN) receptor antagonist that has been shown to decrease lupus flares…Abstract Number: 1601 • ACR Convergence 2023
Interleukin-6 Disrupts Blood-cerebrospinal Fluid Barrier Permeability in Murine Neuropsychiatric Lupus
Background/Purpose: In exploring the pathogenic mechanisms underlying neuropsychiatric lupus (NPSLE), it was discovered that cerebrospinal fluid (CSF) from lupus patients often contains neurotoxic antibodies, cytokines,…Abstract Number: 1705 • ACR Convergence 2023
Reduced DNASE1L3 Activity and Increased Anti-NET Protective Antibodies Contributes to Accumulation of Neutrophil Extracellular Traps in Pediatric SLE Patients
Background/Purpose: Pediatric systemic lupus erythematosus (pSLE) is a multisystemic chronic autoimmune disease with high renal involvement. In SLE, neutrophil extracellular traps (NETs) are considered a…Abstract Number: 2063 • ACR Convergence 2023
Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY): Assessing Behavioral Predictors of Clinical Trial Referrals Among Healthcare Providers
Background/Purpose: The aim of this study is to assess outcomes among healthcare providers in the American College of Rheumatology's (ACR) Training to Increase Minority Enrollment…Abstract Number: 2269 • ACR Convergence 2023
Evaluating Global Patterns in Treatment and Prevalence of Glucocorticoid Related Comorbidities in Systemic Lupus Erythematosus: An International Study
Background/Purpose: Regional disparities in the management of SLE are frequently described. Governance, funding, logistic barriers, and physician choice may be important determinants though data is…Abstract Number: 2286 • ACR Convergence 2023
Systemic Lupus Erythematosus and Functional Work Disability: A Qualitative Perspective Using a Work Disability Prevention Approach
Background/Purpose: Work participation meaningfully influences mental wellbeing, health-related quality of life, and disease-related outcomes in individuals with systematic lupus erythematosus (SLE). Previous studies estimate that…Abstract Number: 2303 • ACR Convergence 2023
Are Neuropsychiatric Symptoms in Systemic Lupus Erythematosus (NPSLE) Associated with More Frequent Hospitalizations or Exposure to a Greater Number of Immunosuppressive Medications?
Background/Purpose: Neuropsychiatric (NP) symptoms occur in >50% of patients with systemic lupus erythematosus (SLE). A major barrier to research includes the non-specific nature of neuropsychiatric…Abstract Number: 2319 • ACR Convergence 2023
Changes in the Causes and Predictors of Lupus Mortality in Spain Through the Last Decades: Data from the RELESSER Registry
Background/Purpose: The mortality in Systemic Lupus Erythematosus (SLE) varies largely across different countries most probably due to social, healthcare and ethnic differences. We need to…
- « Previous Page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- …
- 150
- Next Page »